ResMed (RMD) Acquires Noctrix Health in $340 Million Cash Deal
What happened
ResMed has agreed to acquire Noctrix Health for $340 million, marking an exit for Angelini Ventures, which held Noctrix as its first portfolio company investment. The deal marks Angelini Ventures' first portfolio company exit. The transaction price was confirmed at $340 million. No closing date was specified in the announcement.
The QL Read
RMD shares rose 2.29% to $187.00 on the day of the announcement, while the QuantLogix composite sits at a neutral 44/100. The composite reading below 50 reflects mixed signals as the market absorbs the deal's price tag.
Not financial advice. QuantLogix is a research platform; nothing in this brief constitutes a recommendation to buy or sell any security. We summarize public news with attribution to the original publisher; visit the source above for the full original article.